The National Institutes of Health (NIH) has selected Joshua Denny, MD, MS, vice president of Personalized Medicine at Vanderbilt University Medical Center, to be the chief executive officer of the federal All of Us Research Program.
Prospective mothers taking a new class of cholesterol-lowering drugs might incur higher risk of spina bifida in their future children, according to a study published in the journal Drug Safety by researchers at Vanderbilt University Medical Center.
The first two drugs in the new class, alirocumab and evolocumab, were approved by the Food and Drug Administration in 2015. They’re taken by patients who don’t respond well to first-line therapy.
